EUVIMEDEUVIMED entdecken
Open Access

CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

Swetha Kambhampati Thiruvengadam iD, Kwang Woo Ahn, Jinalben Patel, Qinghua Lian, Mark Hertzberg, Narendranath Epperla iD, Leland Metheny, Sanghee Hong, Tania Jain iD, Mahmoud Aljurf, Amer Beitinjaneh, John Vaughn und 10 weitere

American Journal of Hematology · 2025-10 · 100 (10) · 1803-1812

DOI: 10.1002/ajh.70027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 05.08.2025. Verfasst von Swetha Kambhampati Thiruvengadam und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antigens, CD19, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transformed follicular lymphoma (tFL) is typically associated with chemotherapy resistance and a poor prognosis. There are limited data regarding outcomes after CD19‐directed chimeric antigen receptor T‐cell (CAR T) therapy in relapsed/refractory (R/R) tFL. A total of 923 adult patients with R/R tFL who received commercial CD19 CAR T therapy between 2017 and 2023 were identified in the Center for International Blood and Marrow Transplant Research registry. Median age was 64 years (range: 30–86) and median prior lines of therapy was 4 (range: 1–18). Most patients (78%) received axicabtagene ciloleucel, with 67% of patients having resistant disease at the time of CAR T infusion. At a median follow‐up of 25 months (range: 1–72) from CAR T infusion, the 2‐year overall survival (OS) was 57% (95% CI: 53–60) and progression‐free survival (PFS) was 43% (95% CI: 40–47). The 2‐year cumulative incidences of relapse or progression (rel/prog) and non‐relapse mortality (NRM) were 47% (95% CI: 44–51) and 9% (95% CI: 7–11), respectively. The overall response rate to CAR T was 76%, with a complete response rate of 63%. Grade ≥ 3 cytokine release syndrome (CRS) was observed in 7.1% and grade ≥ 3 immune effector cell–associated neurologic syndrome (ICANS) in 21.6% of patients. Multivariable analysis suggested that resistant disease status at the time of CAR T, use of bridging therapy, and high comorbidity index ≥ 3 were associated with inferior PFS and OS. Older age ≥ 60 significantly increased the risk of NRM. Our study suggests that CD19 CAR T is effective and safe for tFL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntigens, CD19Immunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMiddle AgedAgedMaleAdultFemaleAged, 80 and overRegistriesBiological Products

Stichwörter der Autor:innen

CAR‐Treal worldtransformed follicular lymphoma

Substanzen

Antigens, CD19Receptors, Chimeric Antigenaxicabtagene ciloleucelBiological Products

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
  • Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Seidman Cancer Center, University Hospitals of Cleveland, Cleveland Ohio and Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
  • Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Swetha Kambhampati Thiruvengadam, Narendranath Epperla, Tania Jain, Madiha Iqbal, Baldeep Wirk, Carolina Oliver, Mazyar Shadman, Alex F Herrera

Förderung

  • NIEHS NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Thiruvengadam, S. K., Ahn, K. W., Patel, J., Lian, Q., Hertzberg, M., Epperla, N., Metheny, L., Hong, S., Jain, T., Aljurf, M., Beitinjaneh, A., Vaughn, J., Gopal, A., Iqbal, M., Wirk, B., Manjappa, S., Oliver, C., Mohty, R., Shadman, M., …, & Herrera, A. F. (2025). CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American Journal of Hematology, 100(10), 1803-1812. https://doi.org/10.1002/ajh.70027

Vancouver

Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, et al. CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American Journal of Hematology. 2025;100(10):1803-1812. doi:10.1002/ajh.70027

BibTeX
@article{Thiruvengadam2025,
  author = {Thiruvengadam, Swetha Kambhampati and Ahn, Kwang Woo and Patel, Jinalben and Lian, Qinghua and Hertzberg, Mark and Epperla, Narendranath and Metheny, Leland and Hong, Sanghee and Jain, Tania and Aljurf, Mahmoud and Beitinjaneh, Amer and Vaughn, John and Gopal, Ajay and Iqbal, Madiha and Wirk, Baldeep and Manjappa, Shivaprasad and Oliver, Carolina and Mohty, Razan and Shadman, Mazyar and Turtle, Cameron and Hamadani, Mehdi and Herrera, Alex F},
  title = {CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {10},
  pages = {1803--1812},
  doi = {10.1002/ajh.70027}
}
Kostenlos starten →